Outlook Therapeutics Announces $16.0 Million Private Placement to Advance the Development of ONS-5010 / LYTENAVA™ (bevacizumab-vikg)

Frank Burrell
Scientific Storytelling

Amy Giles
Increasing Engagement

Liz Kane
Impactful Strategy

Suma Ramadas, PhD
Medical Affairs

Matthew Durham
Omnidynamic Marketing

Joey Cohen
Medication Adherence

Daniel Sontupe
Market Access

Stacey Gandler
Brand Nourishment

Bud Bilanich
Success Coach

David Linetsky
Point-of-Care Marketing

Paul Theisen
Patient Acquisition

Pat Purcell
Meeting Engagement

Matt Turner
Patient Affordability

Brenda Snow
Authentic Patient Voice